U.S. Markets open in 7 mins

TG Therapeutics and Three Additional Stocks Under Scanner in the Biotech Space

Stock Research Monitor: TRVN, UTHR, and VNDA

LONDON, UK / ACCESSWIRE / June 08, 2018 / If you want a free Stock Review on TGTX sign up now at www.wallstequities.com/registration. On Thursday, June 07, 2018, the NASDAQ Composite ended the trading session at 7,635.07, down 0.70%; the Dow Jones Industrial Average edged 0.38% higher, to finish at 25,241.41; and the S&P 500 closed at 2,770.37, slightly dropping 0.07%. US markets saw six out of nine sectors finishing the day in red and three in green. This Friday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: TG Therapeutics Inc. (NASDAQ: TGTX), Trevena Inc. (NASDAQ: TRVN), United Therapeutics Corp. (NASDAQ: UTHR), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

TG Therapeutics

New York headquartered TG Therapeutics Inc.'s stock finished Thursday's session 4.12% lower at $13.95 with a total trading volume of 1.11 million shares, which is above its three months average volume of 1.07 million shares. The Company's shares have advanced 10.93% in the last month and 13.41% over the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 0.79% and 20.00%, respectively. Additionally, shares of TG Therapeutics, which focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the US, have a Relative Strength Index (RSI) of 52.00. Get the full research report on TGTX for free by clicking below at:

www.wallstequities.com/registration/?symbol=TGTX

Trevena

On Thursday, shares in Chesterbrook, Pennsylvania headquartered Trevena Inc. recorded a trading volume of 715,672 shares. The stock ended the session 3.74% lower at $1.80. The stock is trading above its 50-day moving average by 0.60. Moreover, shares of Trevena, which develops therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions, have an RSI of 48.37. Get access to our top-rated research, including the free report on TRVN at:

www.wallstequities.com/registration/?symbol=TRVN

United Therapeutics

Silver Spring, Maryland headquartered United Therapeutics Corp.'s shares closed the day 0.25% higher at $110.96. The stock recorded a trading volume of 213,924 shares. The Company's shares have gained 8.86% in the last month. The stock is trading above its 50-day moving average by 2.19%. Additionally, shares of United Therapeutics, which develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide, have an RSI of 58.62. Click here to subscribe for a free membership which welcomes you with our report on UTHR at:

www.wallstequities.com/registration/?symbol=UTHR

Vanda Pharmaceuticals

Shares in Washington, the District of Columbia headquartered Vanda Pharmaceuticals Inc. finished 0.55% lower at $18.00. The stock recorded a trading volume of 179,548 shares. The Company's shares have advanced 11.80% in the last month and 31.39% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 12.13% and 12.04%, respectively. Furthermore, shares of Vanda Pharma, which focuses on the development and commercialization of products for the treatment of central nervous system disorders, have an RSI of 68.96.

On May 23rd, 2018, research firm Citigroup initiated a 'Buy' rating on the Company's stock, with a target price of $26 per share. Join our big investor community at Wall St. Equities today and get your free report on VNDA at:

www.wallstequities.com/registration/?symbol=VNDA

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities